drugset / Trial / NCT05463731
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
RandomizedParallel-groupDouble-blindTreatment
Summary
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
Timeline
- Start
- 2022-08-01
- Primary completion
- 2024-04-24
- Completion
- 2026-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remternetug | Monoclonal antibody | — | Intravenous |